Compare IVT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVT | BEAM |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2005 | 2019 |
| Metric | IVT | BEAM |
|---|---|---|
| Price | $31.73 | $30.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $32.50 | ★ $50.75 |
| AVG Volume (30 Days) | 373.5K | ★ 1.9M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.11% | N/A |
| EPS Growth | ★ 647.37 | 82.31 |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $299,169,000.00 | $24,000.00 |
| Revenue This Year | $7.92 | N/A |
| Revenue Next Year | $5.31 | $32.20 |
| P/E Ratio | $22.63 | ★ N/A |
| Revenue Growth | 9.20 | ★ 33.33 |
| 52 Week Low | $26.52 | $15.52 |
| 52 Week High | $32.63 | $36.44 |
| Indicator | IVT | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 60.92 | 69.32 |
| Support Level | $30.31 | $23.71 |
| Resistance Level | $32.63 | $31.54 |
| Average True Range (ATR) | 0.54 | 1.65 |
| MACD | 0.12 | 0.75 |
| Stochastic Oscillator | 69.21 | 97.48 |
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.